D. Miles

D. Miles, M. Reddish, R. Rubens, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

P. Carmeliet, D. Lambrechts, A. Bansal, 2014, Angiogenesis.

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

D. Miles, J. Pierga, K. Pritchard, 2012, European journal of cancer.

Variations in treatment and survival in breast cancer.

D. Miles, A. Purushotham, S. Pain, 2001, The Lancet. Oncology.

An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas

R. Poulsom, J. Taylor‐Papadimitriou, D. Miles, 1999 .

Changes in mucin‐type O‐glycosylation in breast cancer: implications for the host immune response

J. Taylor‐Papadimitriou, D. Miles, J. Burchell, 2004 .

Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice.

I. Brockhausen, J. Taylor‐Papadimitriou, D. Miles, 2004, International journal of oncology.

Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T

K. Gelmon, J. Baselga, M. Climent, 2007 .

Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2

J. Baselga, D. Miles, D. Cameron, 2005 .

HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors

D. Miles, C. Tsui, M. Pegram, 2019, Clinical Cancer Research.

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

W. Wick, M. Preusser, D. Miles, 2016, Molecular Cancer Therapeutics.

Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.

D. Miles, Kostas Papazisis, 2003, Clinical breast cancer.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, S. Loi, 2020, The Lancet. Oncology.

Safety and efficacy of the combination of trastuzumab with docetaxel for HER2‐positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK

D. Miles, K. Papazisis, T. Habeshaw, 2004, International journal of clinical practice.

Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.

Robin L. Jones, G. Berry, D. Miles, 2004, The Lancet. Oncology.

Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting

D. Miles, 2001, Breast cancer research : BCR.

Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy.

H. Jenkins, A. Tres, J. Mayordomo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Immunotherapy for Breast Cancer: Promises, Promises …

J. Taylor‐Papadimitriou, D. Miles, T. Plunkett, 2000 .

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.

A. Buzdar, B. Xu, D. Miles, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.

N. Robert, D. Miles, Miguel Martín, 2012, European journal of cancer.

Capecitabine and docetaxel in the treatment of metastatic breast cancer: combination, sequence or single agent?

D. Miles, 2008 .

Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).

D. Miles, P. Reichardt, C. Twelves, 2004, Seminars in oncology.

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

D. Miles, L. Mauriac, J. O’Shaughnessy, 2004, Clinical breast cancer.

Setting the Record Straight: Activity of Gemcitabine Monotherapy for Breast Cancer

D. Miles, P. Reichardt, 2004, Oncology.

What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer? A review of the data.

D. Miles, J. Krell, C. Palmieri, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†

K. Blackwell, N. Lin, D. Miles, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Vaccines and Immunotherapy

J. Taylor‐Papadimitriou, D. Miles, J. Burchell, 2000 .

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.

D. Miles, D. Cameron, J. O’Shaughnessy, 2017, European journal of cancer.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

D. Miles, D. Cameron, J. Canon, 2017, European journal of cancer.

Bevacizumab in breast cancer: fundamental questions remain.

D. Miles, 2013, The Lancet. Oncology.

UK guidance document: treatment of metastatic breast cancer.

D. Miles, I. Smith, I. Kunkler, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Quality of life in women with advanced breast cancer treated with docetaxel.

D. Miles, C. Twelves, A. Hall, 2004, Clinical breast cancer.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

N. Robert, D. Miles, I. Smith, 2010, Breast Cancer Research and Treatment.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine

N. Ibrahim, J. Murray, D. Miles, 2004 .

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

D. Miles, I. Smith, A. Calvert, 2001, European journal of cancer.

No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.

A. Schneeweiss, N. Harbeck, D. Miles, 2009 .

Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis.

J. Baselga, D. Miles, J. Cortes, 2010 .

Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer

H. Earl, R. Souhami, D. Geddes, 2004, Cancer Chemotherapy and Pharmacology.

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

H. Gundacker, M. Dowsett, D. Miles, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study

D. Miles, R. Rubens, M. Richards, 2004, Cancer Chemotherapy and Pharmacology.

K. Blackwell, N. Lin, D. Miles, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

R. Gray, E. Perez, D. Miles, 2010 .

Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).

D. Miles, J. O’Shaughnessy, V. Diéras, 2009 .

Response of metastatic breast cancer to trastuzumab?

D. Miles, D. Barnes, 2000, The Lancet.

Expression ofsialyl-Tn predicts theeffect ofadjuvant chemotherapy in node-positive breast cancer

W. Gregory, D. Miles, L. Happerfield, 1994 .

Doxorubicin-paclitaxel - A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial

M. Piccart, M. Nooij, D. Miles, 2003 .

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

N. Ibrahim, J. Murray, D. Miles, 2013, Journal of Cancer.

Abstract P5-16-01: Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial

N. Ibrahim, J. Murray, D. Miles, 2012 .

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.

A. Howell, H. Earl, D. Miles, 1998, Blood.

Protection against MUC1 expressing mouse tumours by intra‐muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain

J. Taylor‐Papadimitriou, D. Miles, J. Burchell, 2004, International journal of cancer.

Abstract P6-12-03: Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC)

D. Miles, G. Romieu, J. O’Shaughnessy, 2010 .

Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy

K. Gelmon, J. Baselga, D. Miles, 2008 .

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.

J. Baselga, K. Blackwell, S. Verma, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer.

H. Earl, R. Souhami, D. Miles, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer

Philip Smith, D. Miles, D. Barnes, 1997, International journal of cancer.

Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

R. Souhami, J. Ledermann, W. Gregory, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer tumour vaccines.

D. Miles, 1997, Cancer treatment reviews.

Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study.

D. Miles, H. Samonigg, J. Beith, 2009 .

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

P. Carmeliet, P. Hegde, G. Jayson, 2011 .

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

P. Carmeliet, D. Lambrechts, A. Bansal, 2014, Angiogenesis.

Genetic markers of bevacizumab-induced hypertension

P. Carmeliet, D. Lambrechts, A. Bansal, 2014, Angiogenesis.

UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.

D. Miles, S. Johnston, I. Smith, 2000, Oncology.

Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.

A. Padhani, D. Koh, A. Makris, 2020, Radiology.

Clinical case Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere) chemotherapy

D. Miles, R. Rubens, A. Hanby, 2005 .

Images in clinical medicine. Transverse leukonychia.

D. Miles, R. Rubens, 1995, The New England journal of medicine.

Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine.

N. Ibrahim, D. Miles, L. Finke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.

J. Taylor‐Papadimitriou, D. Miles, M. Reddish, 1996, British Journal of Cancer.

MUC1 and the Immunobiology of Cancer

J. Taylor‐Papadimitriou, D. Miles, J. Burchell, 2002, Journal of mammary gland biology and neoplasia.

Immunotherapy and breast cancer.

D. Miles, T. Plunkett, 1998, Cancer treatment reviews.

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

D. Amadori, J. Baselga, P. Sunpaweravong, 2013, Breast Cancer Research and Treatment.

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

J. Baselga, D. Miles, D. Cameron, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

O. Chinot, D. Miles, H. Hurwitz, 2020, Cancer treatment reviews.

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

K. Gelmon, J. Baselga, D. Miles, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

A. Tres, J. Mayordomo, N. Ibrahim, 2011, The oncologist.

Chemotherapy of malignant fibrous histiocytoma of bone.

H. Earl, R. Souhami, D. Miles, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of type IV collagenases in benign and malignant breast disease.

D. Miles, L. Happerfield, L. Bobrow, 1993, British Journal of Cancer.

Role of nitric oxide in tumour progression: Lessons from human tumours

L. Thomsen, D. Miles, 1998, Cancer and Metastasis Reviews.

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.

Richard Graham Knowles, S. Moncada, L. Thomsen, 1998, British Journal of Cancer.

Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

J. Baselga, S. Swain, D. Miles, 2014, The oncologist.

Results From the Phase III Trial CLEOPATRA Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From

J. Baselga, S. Swain, D. Miles, 2014 .

A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy

A. Howell, H. Earl, D. Miles, 1998 .

Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue

D. Miles, L. Happerfield, L. Bobrow, 1994 .

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer

D. Miles, 2009, Breast Cancer Research.

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

N. Harbeck, D. Miles, L. Dirix, 2008 .

Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study.

S. Verma, D. Miles, X. Pivot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Family history and survival in premenopausal breast cancer.

D. Miles, D. Barnes, S. Hodgson, 1998, British Journal of Cancer.

Immunotherapy: the last 25 years.

D. Miles, T. Plunkett, 1999, Cancer treatment reviews.

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

H. Burger, D. Miles, L. Mauriac, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sung-Bae Kim, A. Schneeweiss, S. Swain, 2019, Journal of Clinical Oncology.

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer

S Detre, M. Dowsett, B. Sanghera, 2014, British Journal of Cancer.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

C. Caldas, J. Abraham, H. Earl, 2018 .

13. NEW BIOLOGICAL THERAPIES FOR BREAST CANCER

D. Miles, T. Plunkett, D. Miles, 2002, International journal of clinical practice.

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

D. Miles, D. Barnes, R. Rubens, 1999, British Journal of Cancer.

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

C. Caldas, E. Provenzano, J. Abraham, 2020, Health technology assessment.

Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer

A. Padhani, A. Makris, D. Miles, 2017, Targeted Oncology.

Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

D. Miles, V. Diéras, J. Sohn, 2014, Cancer.

Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials.

N. Robert, D. Miles, I. Smith, 2009 .

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

D. Miles, L. Mauriac, L. Dirix, 2009 .

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

E. Van Cutsem, N. Harbeck, D. Miles, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

J. Baselga, S. Swain, D. Miles, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

D. Amadori, J. Baselga, S. Swain, 2013, The oncologist.

Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors.

D. Miles, J. Linehan, P. Smith, 1995, British Journal of Cancer.

Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer.

W. Gregory, D. Miles, L. Happerfield, 1994, British Journal of Cancer.

Reconstitution of interleukin 2 with albumin for infusion

M. Wadhwa, C. Bird, R. Thorpe, 1990, The Lancet.

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2

J. Taylor‐Papadimitriou, D. Miles, P. Beuzeboc, 2003, Journal of biomedicine & biotechnology.

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

A. Schneeweiss, K. Russell, F. André, 2020 .

Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

Philip Smith, D. Miles, D. Barnes, 1999, International journal of cancer.

Molecular approach to breast cancer treatment.

J. Baselga, Y. Yarden, D. Miles, 2004, Seminars in oncology.

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

D. Miles, X. Pivot, A. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

When HER2 is not the target: advances

D. Miles, 2009 .

Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

D. Miles, F. Balkwill, D. Wallach, 1992, British Journal of Cancer.

Consensus on Medical Treatment of Metastatic Breast Cancer

M. Stockler, H. Burstein, J. Bonneterre, 2003, Breast Cancer Research and Treatment.

XELODA® AND TAXOTERE®: A REVIEW OF THE DEVELOPMENT OF THE COMBINATION FOR USE IN METASTATIC BREAST CANCER

D. Miles, F. Mcdonald, 2003, International journal of clinical practice.

489 Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies

D. Miles, J. O’Shaughnessy, V. Diéras, 2010 .

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019, The Lancet.

versus 12 months of adjuvant trastuzumab for HER 2-positive early breast cancer ( PERSEPHONE ) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

C. Caldas, E. Provenzano, J. Abraham, 2019 .

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

H. Earl, D. Miles, D. Cameron, 2018, BMC Cancer.

Trastuzumab-associated cardiac events in the Persephone trial

J. Abraham, H. Earl, D. Miles, 2016, British Journal of Cancer.

J. Baselga, S. Verma, D. Miles, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

J. Abraham, H. Earl, H. Joensuu, 2021, Annals of Oncology.

4 Mechanisms of anticancer drugs

D. Miles, S. Payne, 2007 .

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

H. Earl, D. Miles, A. Wardley, 2018, BMC Cancer.

Management of chemotherapy-resistant breast cancer

D. Miles, R. Rubens, 1996 .

Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma

D. Thomas, R. Souhami, D. Miles, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of a gene-modified vaccinia virus expressing MUC1 and IL-2 (TG1031) in patients with metastatic breast cancer

J. Taylor‐Papadimitriou, D. Miles, R. Acres, 2001 .

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial

S. Swain, D. Miles, M. Beattie, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

C. Caldas, J. Abraham, H. Earl, 2020, Clinics in oncology.

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Sung-Bae Kim, S. Loi, D. Miles, 2019, Journal of Clinical Oncology.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

J. Baselga, N. Robert, D. Miles, 2012, Annals of Oncology.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

J. Baselga, N. Robert, D. Miles, 2019, Annals of Oncology.

Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.

A. Howell, D. Miles, R. Coleman, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

S. Loi, F. Du, D. Miles, 2018 .

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

A. Schneeweiss, Bing-he Xu, F. André, 2018 .

Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor

D. Miles, H. Simonds, 2007, Expert opinion on biological therapy.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

A. Schneeweiss, D. Miles, F. Puglisi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).

S. Loi, S. Adams, F. André, 2022, Journal of Clinical Oncology.

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D. Miles, D. Cameron, J. Canon, 2015 .

Capecitabine plus docetaxel combination therapy

J. Hornberger, D. Miles, J. O’Shaughnessy, 2005, Cancer.

Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]).

R. Greil, S. Barni, D. Miles, 2009 .

Incidence of brain metastases in patients treated with bevacizumab

W. Wick, D. Miles, F. Winkler, 2013 .

Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.

Robin L. Jones, D. Miles, 2005, The Lancet. Oncology.

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

D. Miles, 2012, Drugs.

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab

P. Carmeliet, D. Lambrechts, D. Miles, 2011 .

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK

D. Miles, C. Poole, A. Ratcliffe, 2001 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

A. Schneeweiss, D. Miles, M. Campone, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.

S. Swain, D. Miles, A. Knott, 2015 .

Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast

D. Miles, A. Hanby, D. Barnes, 2001, The Journal of pathology.

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

N. Harbeck, D. Miles, L. Dirix, 2009 .

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

A. Makris, D. Miles, S. Johnston, 2006, Cancer Chemotherapy and Pharmacology.

Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy.

D. Miles, R. Rubens, A. Hanby, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeting angiogenesis in metastatic breast cancer

D. Miles, 2011 .

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

D. Miles, L. Dirix, X. Pivot, 2010 .

D. Miles, V. Diéras, J. Sohn, 2014, Cancer.

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

D. Miles, L. Dirix, J. Cortes, 2011 .

Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer.

D. Miles, S. Sutherland, Andreas Makris, 2016, European journal of cancer.